Dateline City: DURHAM, N.C. Study To Assess Real-Life Clinical Results in 300 Patients With Bifurcation Disease in Italy DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in E-Tryton Italy, a registry study of the company’s Tryton Side Branch Stent™ System. E-Tryton Italy is …
WHAT'S NEW FEATURED ARTICLE Tryton releases interim data for branch stent system
WHAT’S NEW FEATURED ARTICLE Tryton releases interim data for branch stent system Medical Device Daily October 1, 2010 Download PDF
Tryton Announces Positive Six-Month Results for Side Branch Stent System Results Consistently Demonstrate a Rate of Target Lesion Revascularization of Less Than Four Percent in More Than 400 Patients
September 29, 2010: Tryton Announces Positive Six-Month Results for Side Branch Stent System Results Consistently Demonstrate a Rate of Target Lesion Revascularization of Less Than Four Percent in More Than 400 Patients Download PDF
Tryton Announces TCT Activities Symposium to Feature Interim Six-Month Results from More Than 250 Patients Treated with Tryton Stent System
September 17, 2010: Tryton Announces TCT Activities Symposium to Feature Interim Six-Month Results from More Than 250 Patients Treated with Tryton Stent System Download PDF
Tryton Announces TCT Activities
Dateline City: DURHAM, N.C. Symposium to Feature Interim Six-Month Results from More Than 250 Patients Treated with Tryton Stent System DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company will sponsor a symposium on Thursday, Sept. 23, 2010 during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, …
Tryton Completes $20 Million Financing To Accelerate U.S. Pivotal Trial Strong Support from Current Investors and New Investor Arnerich Massena & Associates
September 14, 2010: Tryton Completes $20 Million Financing To Accelerate U.S. Pivotal Trial Strong Support from Current Investors and New Investor Arnerich Massena & Associates Download PDF
Tryton Completes $20 Million Financing To Accelerate U.S. Pivotal Trial
Dateline City: DURHAM, N.C. Strong Support from Current Investors and New Investor Arnerich Massena & Associates DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced that the company has closed a $20 million Series D round of financing. Current investors PTV Sciences, RiverVest Venture Partners and Spray Venture Partners continue to provide …
Tryton Announces Launch in Several European and Eastern European Countries Excellent Six-Month Clinical Results with Target Lesion Revascularization Rate of Less Than Four Percent
September 13, 2010: Tryton Announces Launch in Several European and Eastern European Countries Excellent Six-Month Clinical Results with Target Lesion Revascularization Rate of Less Than Four Percent Download PDF
Tryton Announces Launch in Several European and Eastern European Countries
Dateline City: DURHAM, N.C. Excellent Six-Month Clinical Results with Target Lesion Revascularization Rate of Less Than Four Percent DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company has launched the Tryton Stent System in Switzerland, Sweden, Finland, Turkey, Hungary, Czech Republic, Slovakia and Latvia. “We are pleased to …
Tryton Announces First Implants in Israel More Than 1,300 Patients Treated Worldwide with Tryton Stent System
June 23, 2010: Tryton Announces First Implants in Israel More Than 1,300 Patients Treated Worldwide with Tryton Stent System Download PDF